[6-K] Oncolytics Biotech, Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Bank of New York Mellon Corp. (BK) insider J. Kevin McCarthy has filed Form 144 to sell up to 20,000 common shares via UBS Financial Services on or about 22 Jul 2025. Based on the filing’s reference price, the planned sale equals roughly $1.97 million, or 0.003% of the 715.4 million shares outstanding.

The shares derive from vested employee stock awards granted between 2020-2025. The notice also reveals that McCarthy sold 30,000 shares for $2.37 million on 29 Apr 2025. Rule 144 requires the filer to affirm no knowledge of undisclosed material information and to adhere to volume and timing limits.

The document contains no earnings or operational data; it purely alerts investors to incremental insider selling activity that is small relative to float but may influence sentiment monitoring.

Positive

• Planned sale equals only 0.003% of outstanding shares, implying negligible dilution or ownership shift.

Negative

• Insider J. Kevin McCarthy intends to sell 20,000 shares worth $1.97 million under Rule 144.
• Filer previously sold 30,000 shares for $2.37 million on 29 Apr 2025, indicating continued divestment.

Insights

Securities Analyst

TL;DR Insider McCarthy's Form 144 discloses intent to sell 20k BK shares, adding to 30k shares sold in April; modest but negative sentiment.

The filing signals continued insider monetisation: 20,000 shares (~$1.97 m) now and 30,000 shares (~$2.37 m) already sold within the last quarter. Although the combined 50,000 shares represent a negligible 0.007% of outstanding stock, insider sales can weigh on short-term sentiment, especially when clustered. No performance metrics are provided, so valuation impact is limited to behavioural interpretation. I classify the disclosure as modestly negative and not materially impactful for fundamentals.

Corporate Governance Expert

TL;DR Filing indicates orderly Rule144 sale using UBS; no material undisclosed info claimed; governance compliance evident, limited market impact.

Form 144 is a routine mechanism allowing affiliates to resell shares while maintaining transparency. The filer certifies knowledge of no undisclosed adverse information, aligning with governance best practices. Use of a major broker and adherence to Rule 144 volume/date constraints suggest an orderly process. Because the stake is immaterial relative to float, I view overall market impact as minimal and the filing as procedurally neutral.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of July 2025

Commission File Number 001-38512

Oncolytics Biotech Inc.

(Translation of registrant's name into English)

Suite 804, 322 11th Avenue SW

Calgary, Alberta, Canada T2R 0C5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   þ Form 40-F   o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

EXHIBIT NUMBER						DESCRIPTION
99.1						Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc. (Registrant)

By:

/s/  Kirk Look

Date: July 22, 2025

Kirk Look Chief Financial Officer

FAQ

How many BK shares are proposed for sale in this Form 144?

The filer intends to sell 20,000 common shares of Bank of New York Mellon.

What is the estimated market value of the shares to be sold?

The aggregate market value stated in the filing is $1,972,000.

When is the approximate sale date for the proposed transaction?

The filing lists an approximate sale date of 07/22/2025.

Which broker will execute the sale of BK shares?

The shares will be sold through UBS Financial Services, Inc.

Has the filer sold BK shares in the past three months?

Yes. The filing discloses a prior sale of 30,000 shares on 04/29/2025 for gross proceeds of $2.37 million.

How were the shares being sold originally acquired?

They were obtained via vested employee stock awards granted between 2020 and 2025.